Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibikase Therapeutics (IKT) Short-term Investments (2022 - 2025)

Inhibikase Therapeutics (IKT) has disclosed Short-term Investments for 4 consecutive years, with $39.1 million as the latest value for Q3 2025.

  • Quarterly Short-term Investments rose 1575.91% to $39.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $39.1 million through Sep 2025, up 1575.91% year-over-year, with the annual reading at $41.1 million for FY2024, 904.51% up from the prior year.
  • Short-term Investments for Q3 2025 was $39.1 million at Inhibikase Therapeutics, up from $9.9 million in the prior quarter.
  • The five-year high for Short-term Investments was $41.1 million in Q4 2024, with the low at $2.0 million in Q3 2023.
  • Average Short-term Investments over 4 years is $16.0 million, with a median of $15.9 million recorded in 2022.
  • The sharpest move saw Short-term Investments crashed 90.51% in 2023, then soared 1575.91% in 2025.
  • Over 4 years, Short-term Investments stood at $15.9 million in 2022, then crashed by 74.23% to $4.1 million in 2023, then skyrocketed by 904.51% to $41.1 million in 2024, then fell by 4.87% to $39.1 million in 2025.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $39.1 million, $9.9 million, and $19.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.